Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30943103 | 0.88 | EPHX1 (0.55) | EPHX1MMP1MMP2MEN1KMT2A | |
| SCHEMBL196214 | 0.82 | EPHX1 (0.50) | EPHX1KDM4CGAAMAPTKDM4E | |
| SCHEMBL10603233 | 0.81 | MCL1 (0.52) | EPHX1KDM4CGAAMCL1ALDH1A1 | |
| SCHEMBL1964189 | 0.80 | EPHX1 (0.48) | EPHX1KDM4CGAAMAPTKDM4E | |
| SCHEMBL2834332 | 0.79 | EPHX1 (0.52) | EPHX1KDM4CMAPTKDM4EMCL1 | |
| SCHEMBL2138401 | 0.77 | FNTA (0.41) | EPHX1KDM4CGAAMAPTKDM4E | |
| SCHEMBL2138406 | 0.77 | FNTA (0.41) | EPHX1KDM4CGAAMAPTKDM4E | |
| Dimethylamine SCHEMBL6391439 | 0.77 | MCL1 (0.48) | EPHX1KDM4CGAAMCL1MMP1 | |
| SCHEMBL319971 | 0.75 | EPHX1 (0.71) | EPHX1KDM4CMAPTKDM4EMCL1 | |
| SCHEMBL3991887 | 0.74 | MCL1 (0.71) | EPHX1KDM4CGAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| WO-2008027585-A2 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008027585-A2 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADORA2B, ADORA2A, ADORA3 | EPHX1 1678/4885KDM4C 3899/4885GAA 2048/4885 |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA3 | EPHX1 1541/4885KDM4C 4348/4885GAA 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.